Skip to main content

RPG Life Share Price, RPG Life Stock Price, RPG Life

Dear investor,

Please find below mentioned short term fundamental stock for delivery purpose.

RPG Life Sciences is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).(Source : 201903 Annual Report Page No: 65)

 

Company

CMP

Target

BSE Code

NSE Code

 RPG Life Sciences Ltd.

265

380

532983

RPGLIFE

 

RPG Life Sciences, a part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the Branded Formulations, Global Generics and Synthetic APIs space. The company is a research based, pharmaceutical company, producing a wide range of quality, affordable medicines. Mr. H. V. Goenka is the Chairman of RPG life sciences with promoter shareholding of ~72%. The company has a market cap of Rs433 crore.
 

Investment rationale
 

Diverse product portfolio: RPG Life Sciences operates through three business verticals – API (20% revenue contribution), Domestic Formulations (59%) and International Formulations (21%). RPG has a diverse product portfolio spanning over 10 therapeutic areas including Nephrology, Oncology, Urology, Respiratory, etc. RPG enjoys strong brand recognition in anti-diarrheal, antacid, iron-vitamin, and nephrology segments.
 

Strong outlook for business verticals: Healthcare in India has evolved rapidly from being a product centric industry to a service driven sector, with delivery and medical insurance segments gaining prominence. Driven by increasing sales of generic medicines, continued growth in chronic therapies and greater penetration in rural markets, the domestic formulation market in India is expected to register a double-digit growth over the next five years. The International Formulations business will focus on new products, new partners, new markets and the outlook of this business looks promising. RPG is likely to capitalize these opportunities via brand extensions and new product launches where the company’s core competencies exist would also be chief growth drivers.
 

Robust FY20 performance: For the year FY2020, the company registered a turnaround performance led by the biggest contributing domestic business, which grew over 23%, much ahead of the market growth. Product portfolio rejuvenation, focus on prescription generation and sales force effectiveness enhancement were the key contributors. Overall for the company, all 4 quarters recorded fairly consistent sales and profit performance.

 

SafeSeniors tool to early identification of COVID-19: RPG in association with Seniority has launched “SafeSeniors”, unique predictive analysis tool designed especially to early identification of COVID-19 risk among the elderly people. The tool has been developed in consultation with the leading experts in the areas of infectious diseases, clinical pharmacology.
 

Valuation: The Company has registered ~7.7% & 25.7% CAGR growth on topline & bottomline for last 4 years. The company has almost debt-free status and generates strong return ratios at the end of FY20. At current price, the stock is trading at 11.3x of its one year forward earnings.

Fundamental :-

  • Market Cap:  438.19 Cr.
  • Current Price:  265.30
  • 52 weeks High / Low  351.45 / 142.95
  • Book Value:  106.76
  • Stock P/E: 13.17
  • Dividend Yield: 1.51 %
  • ROCE: 9.84 %
  • ROE: 6.88 %
  • Sales Growth (3Yrs): 5.73 %
  • Listed on BSE and NSE
  • Face Value:  8.00

  • PEG Ratio: 0.55
  • Promoter holding: 72.07 %
  • Pledged percentage: 0.00 %
  • Debt:  6.64 Cr.
  • Price to Earning: 13.17
  • EPS:  17.54
  • Net profit:  29.01 Cr.
  • Profit growth: 208 %
  • Profit growth 7Years: 43.64 %
  • Net profit preceding 12months: 27.57 Cr.
  • Profit growth 3Years: -2.20 %
  • Dividend yield: 1.51 %
  • Debt to equity: 0.04
  • Sales last year:  330.16 Cr.
  • Sales growth: 13.75 %
  • Unpledged promoter holding: 72.07 %
  • Investments:  0.00 Cr.
  • Intrinsic Value:  154.39

 Positive :

Company has reduced debt.
Company is virtually debt free.
Company has been maintaining a healthy dividend payout of 29.42%
Debtor days have improved from 54.71 to 43.00 days.
Negative :
The company has delivered a poor growth of 6.99% over past five years.
Company has a low return on equity of 8.52% for last 3 years.

Duration of recommendation: Short to Medium term.
 

Best Regards,

Labels:

Comments

Post a Comment

Thanks for comments

Popular posts from this blog

Mastek is a provider of vertically-focused enterprise technology solutions.

Dear investor, Please find below mentioned short term fundamental stock for delivery purpose.   Company CMP Target BSE Code NSE Code Mastek Ltd. 401 430 523704 MASTEK Fundamental   Market Cap:    980.70  Cr. Current Price:    401.30 52 weeks High / Low    476.00  /  165.70 Book Value:    323.45 Stock P/E:  7.80 Dividend Yield:  1.99  % ROCE:  18.67  % ROE:  15.06  % Sales Growth (3Yrs):  25.16  % Listed on  BSE  and  NSE Company Website Face Value:    5.00 PEG Ratio:  0.54 Promoter holding:  45.09  % Pledged percentage:  57.00  % Debt:    333.18  Cr. Price to Earning:  7.80 EPS:    45.18 Net profit:    108.86  Cr. Profit growth:  24.44  % Profit growth 7Years:  25.14  % Net profit preceding 12months:  102.26  Cr. Profit growth 3Years:  95.59  % D...
Post a Comment
Read more

The 65th Annual General Meeting of the Shareholders of the state Bank of India

The 65 th  Annual General Meeting of the Shareholders of the Bank is scheduled to be held on Tuesday, 14 th  July 2020, 11.00 a.m. at “ State Bank Auditorium”,  State Bank Bhavan Complex, Madame Cama Road, Mumbai – 400021 (Maharashtra) to discuss and adopt the Balance Sheet and the Profit Loss Accounts of the Bank made upto 31 st  March, 2020. If the conditions are not conducive and the local authorities do not permit to hold physical Annual General Meeting, the Meeting will be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM).  The AGM notice dated 05.06.2020 For further details, please refer to the following link: https://www.sbi.co.in/web/ investor-relations/agm-2015- notice  –  then click on ‘65 th AGM’
Post a Comment
Read more

Who can become a PoSP agent?

Who can become a PoSP agent? With quick and easy registration, training, and certification processes, becoming a PoSP agent has never been simpler. Anyone can become a PoSP agent after being certified. No matter what you do in daily life, with a little skill, you can sell insurance, protect people financially, and earn good incomes with zero investments from your end. Having said that, here are some professions that would be ideally suited: Small business owners who meet regularly with customers Those who have their own individual insurance business Retired bankers Financial consultants Mutual Fund distributors How I can join NJ Insure? The following are the minimum requirements to join NJ Insure as a PoSP agent: Resident of India Attained 18 years of age Passed SSC or equivalent certification (matriculation) PAN Card Aadhar Card Bank account When I can start selling products? As soon as you have registered on the NJ Insure app, you may begin your training for the PoSP test...
Post a Comment
Read more